OS by POD24 and by MZL subtypes. OS from a risk-defining event after diagnosis in patients with MZL who were immediately treated after diagnosis. (A) Patients with MZL: POD24 rate, 18%; 3-year OS POD24, achieve 95% vs fail 53% (P < .001) (HR, 19.5; 95% CI, 8.40-45.4). (B) Patients with SMZL: POD rate, 25%; 3-year OS POD24, achieve 95% vs fail 44% (P < .001). (C) Patients with disseminated MZL (Diss-MZL): POD rate, 20%: 3-year OS POD24, achieve 93% vs fail 33% (P < .001). (D) Patients with ENMZL: POD rate, 16%; 3-year OS POD24, achieve 98% vs fail 71% (P < .001). Association of POD24 with OS could not be assessed for NMZL patients because too few events have been reported in this subgroup to do any inference.